Your shopping cart is currently empty

Napyradiomycin B4 is a derivative of Napyradiomycin that inhibits the RANKL-induced MEK-ERK signaling pathway. It reduces osteoclastogenesis and prevents alveolar bone destruction in experimental periodontitis.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | Napyradiomycin B4 is a derivative of Napyradiomycin that inhibits the RANKL-induced MEK-ERK signaling pathway. It reduces osteoclastogenesis and prevents alveolar bone destruction in experimental periodontitis. |
| In vitro | Napyradiomycin B4 (5 μM, 4 days) inhibits RANKL-induced osteoclast differentiation and promotes the expression of Nrf2-related genes while suppressing the expression of osteoclast-related genes. |
| In vivo | Napyradiomycin B4 (2-12 mg/kg, intraperitoneal injection, 6 days) protects against osteoclast-mediated bone loss in a C57BL/J6 mouse model by inhibiting osteoclast formation, preventing periodontal bone destruction, and demonstrates no significant toxicity. |
| Formula | C25H31Cl3O6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.